Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene TherapyGlobeNewsWire • 06/13/22
Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) RecognitionGlobeNewsWire • 05/24/22
Ocugen shares jump premarket after FDA lifts clinical hold on trial of COVID-19 vaccine candidateMarket Watch • 05/23/22
Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)GlobeNewsWire • 05/23/22
Ocugen, Inc. (OCGN) CEO Shankar Musunuri on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/07/22
Ocugen to Host Conference Call on Friday, May 6 at 8:30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial ResultsGlobeNewsWire • 05/02/22
Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual MeetingGlobeNewsWire • 04/29/22
Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical TrialGlobeNewsWire • 04/25/22